The Crosstalk between microRNAs and Long Non-coding RNAs in Hepatocellular Carcinoma

Xueping Jiang

doi:10.54097/0xsk9p22

Authors

Xueping Jiang

DOI:

https://doi.org/10.54097/0xsk9p22

Keywords:

Hepatocellular Carcinoma, Non-coding RNAs, MicroRNAs, Long non-coding RNAs, Crosstalk, Molecular Targeted Therapy

Abstract

Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors worldwide, with China exhibiting the highest incidence and mortality rates in Asia. Over the past decades, significant progress has been made in the early detection and treatment of HCC. However, the molecular mechanisms underlying hepatocarcinogenesis remain incompletely understood. Increasing evidence indicates that non-coding RNAs (ncRNAs) are crucial regulators of diverse biological and pathological processes, including X chromosome inactivation, transcriptional activation or interference, genomic imprinting, and intranuclear transport. Moreover, accumulating studies have revealed intricate network interactions among different ncRNAs. In particular, the crosstalk between microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) has attracted considerable attention. In this review, we summarize current knowledge regarding miRNA–lncRNA interactions and their functional roles in HCC, aiming to provide novel insights into the development of molecularly targeted therapies for this disease.

Downloads

Download data is not yet available.

References

[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68 (6): 394-424, 2018.

[2] Murakami Y, Kawada N. MicroRNAs in hepatic pathophysiology. Hepatology Research, 2016.

[3] Szabo G, Bala S. MicroRNAs in liver disease. Nature Reviews Gastroenterology & Hepatology 10 (9): 542-552, 2013.

[4] Beermann J, Piccoli M, Viereck J, Thum T. Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiological Reviews 96 (4): 1297-1325, 2016.

[5] Hsu SH, Ghoshal K. MicroRNAs in Liver Health and Disease. Curr Pathobiol Rep 1 (1): 53-62, 2013.

[6] Goto Y, Kojima S, Nishikawa R, Enokida H, Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T, Seki N. The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget 5 (17): 7748-59, 2014.

[7] Zhou C, York SR, Chen JY, Pondick JV, Motola DL, Chung RT, Mullen AC. Long noncoding RNAs expressed in human hepatic stellate cells form networks with extracellular matrix proteins. Genome Med 8 (1): 31, 2016.

[8] Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res 42 (Database issue): D92-7, 2014.

[9] Shen L, Wan Z, Ma Y, Wu L, Liu F, Zang H, Xin S. The clinical utility of microRNA-21 as novel biomarker for diagnosing human cancers. Tumour Biol 36 (3): 1993-2005, 2015.

[10] Leucci E, Patella F, Waage J, Holmstrom K, Lindow M, Porse B, Kauppinen S, Lund AH. microRNA-9 targets the long non-coding RNA MALAT1 for degradation in the nucleus. Sci Rep 3: 2535, 2013.

[11] Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W, Chen K, Xiao H, Li H, Tang K, Ye Z, Huang Q, Xu H. Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression. Mol Cancer Ther 13 (12): 3086-97, 2014.

[12] Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G, Reik W. The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r. Nat Cell Biol 14 (7): 659-65, 2012.

[13] Li H, Yu B, Li J, Su L, Yan M, Zhu Z, Liu B. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget 5 (8): 2318-29, 2014.

[14] Zhuang M, Gao W, Xu J, Wang P, Shu Y. The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. Biochem Biophys Res Commun 448 (3): 315-22, 2014.

[15] Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132 (1): 330-42, 2007.

[16] Cui M, Xiao Z, Wang Y, Zheng M, Song T, Cai X, Sun B, Ye L, Zhang X. Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an miR-9-mediated RXRA signaling pathway. Cancer Res 75 (5): 846-57, 2015.

[17] Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, Chen N, Sun F, Fan Q. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 38 (16): 5366-83, 2010.

[18] Wang Y, Chen F, Zhao M, Yang Z, Li J, Zhang S, Zhang W, Ye L, Zhang X. The long noncoding RNA HULC promotes liver cancer by increasing the expression of the HMGA2 oncogene via sequestration of the microRNA-186. J Biol Chem 292 (37): 15395-15407, 2017.

[19] Fu WM, Zhu X, Wang WM, Lu YF, Hu BG, Wang H, Liang WC, Wang SS, Ko CH, Waye MM, Kung HF, Li G, Zhang JF. Hotair mediates hepatocarcinogenesis through suppressing miRNA-218 expression and activating P14 and P16 signaling. J Hepatol 63 (4): 886-95, 2015.

[20] Su DN, Wu SP, Chen HT, He JH. HOTAIR, a long non-coding RNA driver of malignancy whose expression is activated by FOXC1, negatively regulates miRNA-1 in hepatocellular carcinoma. Oncol Lett 12 (5): 4061-4067, 2016.

[21] Yang T, He X, Chen A, Tan K, Du X. LncRNA HOTAIR contributes to the malignancy of hepatocellular carcinoma by enhancing epithelial-mesenchymal transition via sponging miR-23b-3p from ZEB1. Gene 670: 114-122, 2018.

[22] Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z, Boldanova T, Andersen JB, Hammerle M, Tornillo L, Heim MH, Diederichs S, Cillo C, Terracciano LM. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology 59 (3): 911-23, 2014.

[23] Tsang FH, Au SL, Wei L, Fan DN, Lee JM, Wong CC, Ng IO, Wong CM. Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR-125b. Liver Int 35 (5): 1597-606, 2015.

[24] Ge Y, Yan X, Jin Y, Yang X, Yu X, Zhou L, Han S, Yuan Q, Yang M. fMiRNA-192 and miRNA-204 Directly Suppress lncRNA HOTTIP and Interrupt GLS1-Mediated Glutaminolysis in Hepatocellular Carcinoma. PLOS Genetics 11 (12): e1005726, 2015.

[25] Wang F, Ying HQ, He BS, Pan YQ, Deng QW, Sun HL, Chen J, Liu X, Wang SK. Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget 6 (10): 7899-917, 2015.

[26] Xiao JN, Yan TH, Yu RM, Gao Y, Zeng WL, Lu SW, Que HX, Liu ZP, Jiang JH. Long non-coding RNA UCA1 regulates the expression of Snail2 by miR-203 to promote hepatocellular carcinoma progression. J Cancer Res Clin Oncol 143 (6): 981-990, 2017.

[27] Lin X, Huang Z, Chen X, Wu F, Wu W. XIST Induced by JPX Suppresses Hepatocellular Carcinoma by Sponging miR-155-5p. Yonsei Medical Journal 59 (7): 816, 2018.

[28] Chang S, Chen B, Wang X, Wu K, Sun Y. Long non-coding RNA XIST regulates PTEN expression by sponging miR-181a and promotes hepatocellular carcinoma progression. BMC Cancer 17 (1), 2017.

[29] Deng L, Yang SB, Xu FF, Zhang JH. Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge. J Exp Clin Cancer Res 34: 18, 2015.

[30] Dou C, Sun L, Jin X, Han M, Zhang B, Li T. Long non-coding RNA colon cancer-associated transcript 1 functions as a competing endogenous RNA to regulate cyclin-dependent kinase 1 expression by sponging miR-490-3p in hepatocellular carcinoma progression. Tumour Biol 39 (4): 1010428317697 572, 2017.

[31] Hu L, Ye H, Huang G, Luo F, Liu Y, Liu Y, Yang X, Shen J, Liu Q, Zhang J. Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21. Tumour Biol 37 (2): 2691-702, 2016.